| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/01/2001 | CA2382674A1 Gas1 polypeptides |
| 03/01/2001 | CA2382670A1 Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications |
| 03/01/2001 | CA2382666A1 Modulation of the blood-brain barrier transporter for leptin |
| 03/01/2001 | CA2382648A1 Drug treatment for restless leg syndrome |
| 03/01/2001 | CA2382183A1 New g-protein coupled receptor and dna sequences thereof |
| 03/01/2001 | CA2382101A1 A transmembrane trap for isolating membrane bound proteins |
| 03/01/2001 | CA2382045A1 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 03/01/2001 | CA2381571A1 Phospholipid gel |
| 03/01/2001 | CA2381468A1 Percutaneous absorption preparations containing melatonin receptor agonist for percutaneous treatment of sleep disorders |
| 03/01/2001 | CA2381425A1 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 03/01/2001 | CA2380730A1 Solid wound healing formulations containing fibronectin |
| 03/01/2001 | CA2380524A1 Compositions and methods for treating opiate intolerance |
| 03/01/2001 | CA2380513A1 Methods for treatment of mental disorders |
| 03/01/2001 | CA2376180A1 Oral liquid compositions |
| 02/28/2001 | EP1078637A2 Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug |
| 02/28/2001 | EP1078633A2 Compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| 02/28/2001 | EP1078632A1 Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 02/28/2001 | EP1078630A1 Use of sigma receptor agonists for the treatment of depression |
| 02/28/2001 | EP1078073A1 Chitinase chitin-binding fragments |
| 02/28/2001 | EP1078060A2 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 02/28/2001 | EP1078058A2 Prostate growth-associated membrane proteins |
| 02/28/2001 | EP1078057A2 Cell signaling proteins |
| 02/28/2001 | EP1078053A2 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
| 02/28/2001 | EP1078006A1 Diagnosis and treatment of hepatic disorders |
| 02/28/2001 | EP1077997A2 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins |
| 02/28/2001 | EP1077983A2 Pria |
| 02/28/2001 | EP1077949A2 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
| 02/28/2001 | EP1077725A2 Topical pharmaceutical compositions useful for treating cutaneous or circulatory pathologies on inflammatory, immune, proliferative or degenerative basis, comprising pollen extract and vegetable oil unsaponifiables |
| 02/28/2001 | EP1077724A2 Methods and products related to metabolic interactions in disease |
| 02/28/2001 | EP1077723A1 Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
| 02/28/2001 | EP1077716A1 Method for the treatment of gastroesophageal reflux disease |
| 02/28/2001 | EP1077715A1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process |
| 02/28/2001 | EP1077709A1 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies |
| 02/28/2001 | EP1077708A1 Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
| 02/28/2001 | EP1077707A1 Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis |
| 02/28/2001 | EP1077706A1 Ionophore containing composition for modulating amyloidosis |
| 02/28/2001 | EP1077705A1 Potassium channel agonists |
| 02/28/2001 | EP1077704A1 Combination therapy for treatment of depression |
| 02/28/2001 | EP1077702A1 Peripheral benzodiazepine receptor ligands |
| 02/28/2001 | EP1077700A1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE |
| 02/28/2001 | EP1077695A2 COMPOUNDS HAVING IgE AFFECTING PROPERTIES |
| 02/28/2001 | EP1077690A1 Use of amyloid inhibitors for modulating neuronal cell death |
| 02/28/2001 | EP1077689A1 Acylpeptide protease inhibitors to enhance cognitive function |
| 02/28/2001 | EP1077684A1 Effervescent preparations |
| 02/28/2001 | EP1077678A1 Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| 02/28/2001 | CN1285751A Antimutagenic compositions for treatment and prevention of photodamage to skin |
| 02/28/2001 | CN1285747A Combination therapy for treating AIDS |
| 02/28/2001 | CN1285744A Use of histamine for elevating blood histamine levels |
| 02/28/2001 | CN1285742A Combination of active principles for treating senile dementia such as alzheimer dementia |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194455 Prevention herpes outbreak; administering sucralfate, lidocaine and antibiotic |
| 02/27/2001 | US6194440 Small molecule carbamate or urea hair growth compositions and uses |
| 02/27/2001 | US6194431 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 02/27/2001 | US6194426 5,6,7,8 tetrahydroindolizines derivatives |
| 02/27/2001 | US6194401 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of α-glycerophosphoric acid |
| 02/27/2001 | US6194392 Administering to a patient suffering from swelling associated with brain tumours involving tissue of the group consisting of underperfused tissue and pathological tissue an antiswelling agent and a hyaluronic acid to aid penetration |
| 02/27/2001 | US6194391 Cs-87 (title compound) induces a transient mutation in hiv-1 at the 70th codon of the reverse transcriptase region of the virus; administering to a human in need of therapy with a drug that induces a mutation in hiv-1 at another location |
| 02/27/2001 | US6194390 Administering hydroxyurea and a 2'-fluoropurine-dideoxy-nucleoside selected from the group of 2'-fluoro-2',3'-dide-oxyadenosine,-dideoxyinosine, and -dideoxyguanosine with a carrier or excipient; viricides; retroviruses; plant viruses |
| 02/27/2001 | US6194206 Use of oligonucleotide telomerase inhibitors to reduce telomere length |
| 02/27/2001 | US6193997 Proteinic drug delivery system using membrane mimetics |
| 02/27/2001 | US6193970 Potentiating local inflammatory or immune response to administration of tumor antigen in mammalian subject by administering tumor antigen in form of tumor cells, or subcellular antigenic material and cytokine or cytokines |
| 02/27/2001 | CA2317064A1 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 02/27/2001 | CA2316662A1 Use of crf antagonists and related compositions |
| 02/22/2001 | WO2001013121A1 Methods for identification of compounds stimulating insulin secretion |
| 02/22/2001 | WO2001013108A1 Method for identifying modulating compounds of neurotransmitters |
| 02/22/2001 | WO2001013031A2 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | WO2001012819A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | WO2001012805A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012718A1 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 02/22/2001 | WO2001012674A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | WO2001012673A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012663A2 Hematopoietic regulatory factors and methods of use thereof |
| 02/22/2001 | WO2001012662A2 Membrane associated proteins |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012236A2 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 02/22/2001 | WO2001012228A2 Compositions for treating viral infections, and methods therefor |
| 02/22/2001 | WO2001012227A1 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
| 02/22/2001 | WO2001012217A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 02/22/2001 | WO2001012212A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | WO2001012210A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | WO2001012202A2 Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 02/22/2001 | WO2001012192A2 Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil |
| 02/22/2001 | WO2001012190A1 Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012184A1 Neurotherapeutic composition and method |
| 02/22/2001 | WO2001012182A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | WO2001012177A1 Formation of nanometer-scale structures |
| 02/22/2001 | WO2001012176A2 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| 02/22/2001 | WO2001012175A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | WO2001012174A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | WO2001012173A1 Low concentration pest treatment composition and method |
| 02/22/2001 | WO2001012172A1 Treatment of metastatic disease |
| 02/22/2001 | WO2001012171A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 02/22/2001 | WO2001012168A2 Antiviral pharmaceutical compositions containing iron chelators |
| 02/22/2001 | WO2001012160A1 Microparticles for pulmonary administration |
| 02/22/2001 | WO2001012156A1 Topical organic ectoparasiticidal formulations |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |